Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | MMP9 | P14780 | 2/20 | 0.74 |
| ▸ | MMP12 | P39900 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641234 | 1.00 | MMP1 (0.74) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL639348 | 0.85 | CYP2D6 (1.00) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL639349 | 0.85 | CYP2D6 (1.00) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL640810 | 0.81 | MMP1 (0.74) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL640809 | 0.81 | MMP1 (0.74) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL639666 | 0.81 | CYP2D6 (0.82) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL639667 | 0.81 | CYP2D6 (0.82) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL641626 | 0.81 | MMP1 (0.83) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL641625 | 0.81 | MMP1 (0.83) | MMP1CYP2D6MMP9MMP12KCNH2 | |
| SCHEMBL642532 | 0.81 | MMP1 (0.83) | MMP1CYP2D6MMP9MMP12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119692-B2 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2009008920-A2 | HYDROXAMIC ACID DERIVATIVES OF 4-PHENYL 4-HYDROXY, 4-PHENYL 4-ALKOXY AND 4-PHENYL 4-ARYLALKOXY BUTYRIC ACID USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARMA, LLC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | ANTXR2, ABAT, BAX | MMP1 3223/4885CYP2D6 475/4885MMP9 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.